Operating Metrics 營運指標
BeOne Medicines AG (6160.HK) Operating Metrics 營運指標
BeOne Medicines AG 6160.HK 最近 4 季公司營運 KPI、指標定義、跨期趨勢與官方來源。
資料截至：2026-06-30
最新營運指標
- BRUKINSA Global Sales
- 1,248 USD M · 2026-06-30 來源：BeOne Medicines Ltd.
- BRUKINSA U.S. Sales
- 893 USD M · 2026-06-30 來源：BeOne Medicines Ltd.
- TEVIMBRA Global Sales
- 229 USD M · 2026-06-30 來源：BeOne Medicines Ltd.
- Amgen In-Licensed Products Sales
- 157 USD M · 2026-06-30 來源：BeOne Medicines Ltd.
- Product Gross Margin
- 90.0% · 2026-06-30 來源：BeOne Medicines Ltd.
季度趨勢
| 指標 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| BRUKINSA Global Sales | 1,248 USD M | 1,100 USD M | 1,100 USD M | 950 USD M |
| BRUKINSA U.S. Sales | 893 USD M | 761 USD M | 845 USD M | — |
| TEVIMBRA Global Sales | 229 USD M | 206 USD M | 182 USD M | 194 USD M |
| Amgen In-Licensed Products Sales | 157 USD M | 142 USD M | 112 USD M | — |
| Product Gross Margin | 90.0% | 89.0% | 90.4% | 87.0% |
資料來源
- BeOne Medicines Second Quarter 2026 Results and Business Updates · BeOne Medicines Ltd. · 2026-08-05
- BeOne Medicines First Quarter 2026 Results and Business Updates · BeOne Medicines Ltd. · 2026-05-06
- BeOne Medicines Fourth Quarter and Full Year 2025 Results · BeOne Medicines Ltd. · 2026-02-26